Fresh analysis suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional diet and exercise regimens.
Research printed in a major health publication shows that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using such medications must be cognizant of the risk of rapid weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment weight within about a year and a half.
Analyzing Therapies
The research, which examined dozens of trials involving thousands of patients, contrasted the effects of the injectable medications with other pills.
Researchers note that people who shed pounds through diet and exercise usually see a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists suggest the mode of action of the jabs accounts for the accelerated regain.
The injections copy a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to appetite is unsuppressed, making overeating far more likely."
A Chronic Issue?
The NHS advise the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, due to the significant potential of relapse, the therapy is often ongoing.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the chronic nature of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
Users who have stopped the medication report a intense return of cravings.
"It was like a trigger activating and I was suddenly extremely hungry," recalled one woman.
This difficulty is worsened if individuals have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates show that a significant number of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, experts emphasize that while these medications are potent tools for shedding pounds, they are not a standalone cure and long-term success likely depends on combined behavioural management.
